Navigation Links
Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)
Date:4/26/2008

Genomics improves our ability to target experimental cancer treatments

A promising new drug is in hand, and more are on the way

Improved ability to select patients to test particular drugs

MILAN, Italy, April 27 /PRNewswire/ --

At today's sessions of this, the final day of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), leading hepatologists described several important advances in understanding and provide novel treatments for hepatocellular carcinoma (HCC). Most notably, progress has been made by acquiring data that improve our understanding of the disease process at the molecular level... what is taking place in the body that leads to the development of HCC.

Applying the technologies of genomics and microarrays, scientists have discovered that there are a number of different biological pathways that result in HCC. Using this knowledge, they can now classify and explore various subtypes of HCC. This novel view contradicts the previous belief that the disease occurs in one way only, from a single disease mechanism.

The discovery of subtypes has significant implications. First, it raises the possibility of targeting treatments to particular patients, based on their respective cancer subtype ("targeted therapeutics"). Second, it enables more precise assessment of the response to specific experimental therapies. Moreover, it offers the possibility of refining each patient's prognosis, again based on his or her cancer subtype.

Malignancy is a complex process. It involves the accumulation of multiple independent gene mutations that lead to deregulation of cell pathways that influence cell growth and cell fate. The process itself is called the "oncogenic pathway." In the past, most scientists in the field believed that there was only one oncogenic "pathway" in HCC.

HCC is one of the most common tumors worldwide. Most cases of HCC result from a viral infection (Hepatitis B or C) or from cirrhosis. Obesity is an additional, recently recognized risk factor for HCC. Treatment options of HCC and prognosis are dependent on various factors, but chiefly on tumor size and staging.

Only a minority of hepatocellular carcinomas can be removed completely using surgery, and the tumor tends to recur. Other techniques are available to halt tumor progression, including percutaneous therapies such as radiofrequency ablation.

According to Professor Massimo Levrero, Associate Professor of Medicine at Italy's University of Cagliari, and Head of the Laboratory of Gene Expression, Fondazione Andrea Cesalpino, University of Rome La Sapienza, "Molecular approaches are starting to pay off. The years 2007 and 2008 are the 'years of the drug' for HCC. We now have Sorafenib, the first molecular targeted therapy for HCC that has been proven effective in a large clinical trial of patients with advanced cancers. Other drugs are coming soon. While Sorafenib is an efficient drug, our results need to be improved. We want to increase the cytotoxic potential of our treatments by combining drugs that can theoretically yield a synergistic effect. With recent advances regarding HCC subtypes, we know which patients can be selected for response to particular experimental therapies."

Scientists are continuing their search for the genes that are dysregulated in HCC. It is hoped that by improving our ability to identify aberrant genes, research will lead to the identification of new and more powerful pharmacological interventions for HCC.

About EASL

The European Association for the Study of the Liver (EASL) aims to promote investigation into liver disease and improve the treatments that currently exist for these conditions. The association, through its annual meetings, seeks to inform and educate both the scientific community as well as society in general about the increasing occurrence of liver diseases along with the importance of understanding these conditions in order to treat and prevent them. Since its creation in 1966, the EASL congress has been hosted in 20 different European countries. Currently the association has over 1400 members and the annual congress attracts over 6000 delegates from over 65 countries each year.


'/>"/>
SOURCE EASL - European Association for the Study of the Liver
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
4. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
5. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
6. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
7. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
8. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
9. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD is pleased to announce it ... for trading on the TSX Venture Exchange.  ... follows a year of significant achievements for Invictus-MD. Some ... test crops at AB Laboratories Inc. ("AB Labs"), a ...
(Date:3/27/2017)... -- The global clinical chemistry analyzers ... 2025, according to a new study by Grand View ... anticipated to be responsible for the high urgency to ... for growth during the forecast period. In addition, growing ... susceptible to chronic diseases, is presumed to impel the ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... Birmingham, Clarkston, and Lake Orion, Michigan (PRWEB) , ... ... ... can affect weight loss results. The comprehensive weight management program at Women’s ... begins with an initial evaluation and physical exam. The specialists at ...
(Date:3/27/2017)... Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in ... of the best days I’ve had in a long time,” she said. , She thinks ... lot of money that I never thought I would have to help my students.” , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
Breaking Medicine News(10 mins):